Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate

Stealth BioTherapeutics (NASDAQ:MITO) presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.

The new SBT-272 preclinical data demonstrated functional improvement in upper motor neurons with TDP-43 pathology, playing a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.